Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
24
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Vaboo is a customisable perks and engagement platform for the private rented sector. The platform allows clients to enhance their brand image and add value to their service through engaging communication, giveaways, and prize draws, designed to attract customers to the platform on a regular basis. Addressing core problems of the sector, Vaboo not only helps clients built their brand value, it also offers them a competitive edge in the market. By April 2019, 350+ agency branches will have brought 50,000+ renters on to the platform. Moreover, Vaboo is estimated to achieve at least a 10% market share (approx. 2000 branches) which will generate annual recurring revenues of over £4m. With the fund raised, Vaboo will focus on team expansion, product development, and sales.
days to go:
Expired
investment:
£172,077
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.
days to go:
Expired
investment:
£1,386,200
SeedStream is a digital content platform that uses Artificial Intelligence (AI) to combine articles, videos and podcasts into personalised feeds based on user interests. The company has built a prototype focussing on Formula 1 motorsport that aggregates free-to-access news articles and YouTube videos alongside social media posts from the drivers and teams to cover stories from every angle. SeedStream aims to be a disruptor in the 580 million subscription services market. The company will use the investment to develop its prototype into a complete platform, produce original content based on trending topics, and accelerate into different markets.
days to go:
Expired
investment:
£40,843
Musations is a mobile application that allows you to describe your feelings through music. You can share, discover, create and discuss music with friends. Using Musations, you're able to create lip-syncs, free format music videos and voice recordings.
days to go:
Expired
investment:
£63
Like a lot of young independent British film companies, 721 Productions had only a modest budget with which to enter the $36 billion global film industry in 2014 (an industry that seems recession proof given that global box office revenues have seen a 22% increase since 2009).
Despite the low budget, director Paul Emmanuel still produced a piece of brilliance with ‘The Maid’ - a romantic drama that hit the silver screen in early 2014 and subsequently went on to pick up various film accolades, including multiple awards, a nomination for Best UK Feature Film and screenings at the prestigious London and New York film festivals.
Since the overwhelming response to what was 721 Productions' very first film, the team has been hard at work on its latest film ‘Secrets of the Lost Souls’.
Paul Emmanuel is once again steering the ship second time around – albeit with a greater depth of industry connections and knowhow compared to the first. He is working alongside other talented and versatile filmmakers David C. G. Hare – who himself has built an impressive career over the past 15 years – and the award-winning cinematographer Steven Marshall who has over 9 years experience in his field and has worked on movies screened at film festivals in Cannes, Venice and Berlin.
The latest film production will cost £80,000 – you'd be forgiven for thinking that that's a small amount for the production of a movie. But with advanced digital cinema technology available to modern-day filmmakers at reasonable prices, costs can be contained. The film ‘Paranormal Activity’ for example, cost $15,000 to make and grossed over $107,000,000 at the box office – testament not only to the relatively small investment these types of productions need, but also to why Horror/Action genres are widely recognised as offering the highest rates of return on investment in the movie industry.
Like Paranormal Activity ‘Secrets of the Lost Souls’ is a supernatural horror thriller aimed at the more lucrative US market.
Production is scheduled to begin early next year and 721 Productions wants to make investors become part of the journey – one featuring ongoing film updates, special mentions, exclusive screenings, site visits, film previews and a wrap party. How far you travel on that journey with the production team depends on how much you invest.
Investors pledging money to this pitch will receive exciting investor rewards and shares in a movie from what is an emerging British film production company. Check out the 'rewards' section for more details.
days to go:
Expired
investment:
£24,700
MET Homes provides an off-the-shelf modern construction method (MMC) for housing, aiming to make MMC financially viable at lower production volumes, which addresses an identified market gap. Their system utilizes 13 pre-engineered and factory-assembled load-bearing wall and floor panels, suitable for constructing residential new builds up to three stories high. With a selection of 13 panels, MET Homes has developed over 50 house types in different widths, lengths, and roof styles, offering versatility for construction projects.
days to go:
Expired
investment:
£110,602
